View Item 

Show simple item record

Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial
dc.contributor.authorDana, Bruce W.en_US
dc.contributor.authorDahlberg, Steveen_US
dc.contributor.authorSchnitzer, Bertramen_US
dc.contributor.authorKjeldsberg, Carl R.en_US
dc.contributor.authorJones, Stephen E.en_US
dc.contributor.authorCarden, Juanen_US
dc.contributor.authorMundis, Richarden_US
dc.contributor.authorTranum, Bill L.en_US
dc.date.accessioned2006-09-11T15:54:54Z
dc.date.available2006-09-11T15:54:54Z
dc.date.issued1989-07en_US
dc.identifier.citationDana, Bruce; Dahlberg, Steve; Schnitzer, Bertram; Kjeldsberg, Carl R.; Jones, Stephen E.; Carden, Juan; Mundis, Richard; Tranum, Bill; (1989). "Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial." Investigational New Drugs 7 (2-3): 247-250. <http://hdl.handle.net/2027.42/45311>en_US
dc.identifier.issn0167-6997en_US
dc.identifier.issn1573-0646en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/45311
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2793382&dopt=citationen_US
dc.description.abstractA phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma. All patients had relapsed after only one prior chemotherapy regimen (CHOP — 56%; mBACOD — 28%). There were three complete and eight partial responses (overall response rate — 34%) among 32 eligible patients. The median duration of remission was 6.0 months. Severe granulocytopenia was common, with 19/32 patients (63%) suffering life-threatening, and 1/32 (3%) suffering fatal, granulocytopenia.en_US
dc.format.extent270494 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherOncologyen_US
dc.subject.otherNon-Hodgkin's Lymphomaen_US
dc.subject.otherChemotherapyen_US
dc.subject.otherCisplatinumen_US
dc.subject.otherMitoxantroneen_US
dc.subject.otherMethyl Glyoxal Bis-guanyl Hydrazoneen_US
dc.titleMitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trialen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, USAen_US
dc.contributor.affiliationotherOregon Health Sciences University, USAen_US
dc.contributor.affiliationotherSouthwest Oncology Group Statistical Center, Seattle, USAen_US
dc.contributor.affiliationotherUniversity of Utah Medical Center, USAen_US
dc.contributor.affiliationotherArizona Cancer Center, USAen_US
dc.contributor.affiliationotherSt. Louis CCOP, USAen_US
dc.contributor.affiliationotherMidwest CCOP, USAen_US
dc.contributor.affiliationotherArkansas CCOP, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2793382en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/45311/1/10637_2004_Article_BF00170868.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00170868en_US
dc.identifier.sourceInvestigational New Drugsen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10637_2004_Article_BF00170868.pdf
Size:
264.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.